Substituted pyrimidines as prostaglandin D2 receptor antagonists

The present invention is directed to a substituted pyrimidine compound of formula (I) as set forth herein, or an enantiomer thereof, or a prodrug or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising such a compound. The invention also includes a method of treatment of a patient by the administration of a pharmaceutically effective amount of such a compound. Formula (I), wherein m and n, independently of each other, are selected from the integers 0, 1, 2 or 3; X and Y, independently of each other, are selected from CRR, NR or O, wherein X and Y cannot both be O; or X and Y, taken together with the bond between them, form a phenyl group optionally substituted by one to four R groups; each Z, independently of each other, is CRR; R, R and R, independently of each other, are selected from the group consisting of H, halogen, aryl, amino, optionally substituted alkyl, optionally substituted alkoxy, and carboxy; wherein optionally substituted alkyl, may be substituted by one to th